What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Reference-name product · exact chemical identity not independently confirmed
Overview
Reference-name product · exact chemical identity not independently confirmed Vialdyne releases Prostamax as a lyophilized peptide against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Buyers for longevity-class peptides span research labs working on telomere, collagen, and circadian-rhythm models, plus cosmetic-formulation OEMs incorporating peptides like GHK-Cu into anti-aging finished products. Copper peptides in particular require attention to chelator-free water and EDTA-free buffers in downstream formulation work, incompatibility there is the most common cause of "the peptide didn't work" support tickets in this class.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Copper peptides require chelator-free water and EDTA-free buffers in downstream formulation work.
Primary buyer fit: academic and contract research laboratories.
Specifications
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Frequently asked questions
PROSTAMAX is positioned within the broader Russian-school short-peptide bioregulator framework that overlaps with the Khavinson research lineage, both share the design pattern of short tissue-specific peptide preparations marketed for the corresponding tissue indication. The exact composition of PROSTAMAX is proprietary to the upstream manufacturer and may or may not be a single defined peptide (some PROSTAMAX preparations are multi-peptide extracts similar to Cerebrolysin or Cortexin). Vendor and community materials commonly identify it as the tetrapeptide Lys-Glu-Asp-Pro (KEDP), and a PubChem record and one PubMed-indexed paper (PMID 23221144) do use the "Prostamax" name for that sequence — but this falls short of a definitive, independently replicated confirmation that every batch sold under the trade name is this specific molecule. Buyers conducting research with PROSTAMAX should request explicit composition disclosure from the regulatory team and reference the original Russian-language publications if replicating published protocols, rather than assume mechanistic equivalence to named single-peptide Khavinson products.
Russian-school publications on prostate-targeting short peptides focus on age-related benign prostatic hyperplasia (BPH) and prostate-tissue gene-expression modulation in aged-rodent models. The mechanism hypothesis within the Khavinson framework is that short tissue-specific peptides isolated from young-animal prostate tissue can act as endogenous-mimetic bioregulators of prostate gene expression, supporting tissue homeostasis and counteracting age-related dysregulation. For the specific KEDP sequence commonly associated with the PROSTAMAX trade name, the one paper we could independently verify (Dzhokhadze et al., Georgian Med News 2012, PMID 23221144) studied chromatin decondensation in aged human lymphocyte cultures rather than prostate tissue directly. Other prostate-specific animal studies frequently cited for PROSTAMAX in vendor marketing reference a journal name that could not be found in any indexed database, so they are not repeated here as evidence. As with the broader Khavinson framework, the verifiable evidence base is thin and concentrated in Russian-language, institute-affiliated publications; PROSTAMAX should be treated as an investigational research tool of uncertain precise identity rather than a clinically-validated prostate therapeutic.
